Mississippi's 39.5% adult obesity rate is the highest in the nation (CDC 2023). Approximately 650,000 Mississippians have diagnosed diabetes — the highest rate per capita in the US. Across metro areas like Jackson, Gulfport, Southaven, Hattiesburg, obesity-related conditions including type 2 diabetes, hypertension, and cardiovascular disease affect hundreds of thousands of Mississippi residents every year.
GLP-1 receptor agonists — semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are FDA-approved prescription medications that produce average weight loss of 15–22% of body weight in clinical trials, with proven reductions in cardiovascular event risk. Thanks to Mississippi's telehealth law (Mississippi Code § 73-25-34), these medications are now accessible from any city or rural county in the state through a licensed online physician.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Complete a secure health questionnaire from anywhere in Mississippi — Jackson, Gulfport, Southaven, Hattiesburg, or any rural county. Takes under 10 minutes.
A board-certified MD licensed in Mississippi reviews your health profile and conducts a HIPAA-compliant telehealth consultation — within 24–48 hours.
If approved, your GLP-1 medication ships from a licensed US pharmacy directly to your Mississippi address — no pharmacy trip, no waiting room.
Licensed telehealth GLP-1 providers serve every corner of Mississippi. Select your city below for local information and to start your consultation.
Whether you live in urban Hinds County, or a rural county, our Mississippi-licensed telehealth providers can prescribe GLP-1 medications online. Choose your county:
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Mississippi telehealth law (Mississippi Code § 73-25-34) explicitly permits licensed physicians to prescribe medications — including GLP-1 receptor agonists — via telemedicine after a valid patient-physician relationship is established through an online consultation. You do not need to visit a clinic in person.
Mississippi has an adult obesity rate of 39.5%, ranking 1st — highest in the US in the United States. Cities such as Jackson, Gulfport, Southaven see high rates of obesity-related conditions including type 2 diabetes and cardiovascular disease. GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are clinically proven to reduce body weight by 15–22% and improve metabolic health markers.
Mississippi-licensed telehealth providers can prescribe all FDA-approved GLP-1 medications, including semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), and liraglutide (Saxenda for weight loss, Victoza for diabetes). Eligibility is assessed individually during your consultation.
Most Mississippi patients complete their free health assessment online and receive a physician consultation within 24–48 hours. If approved, your prescription is sent to a licensed US pharmacy and medications typically arrive within 3–5 business days by home delivery — no in-person pharmacy visit required.
Mississippi Medicaid may cover GLP-1 medications when prescribed for FDA-approved type 2 diabetes indications. Coverage for weight loss indications (Wegovy, Zepbound) varies by commercial insurance plan. Manufacturer patient assistance and savings programs can significantly reduce out-of-pocket costs for eligible Mississippi residents who do not have coverage.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
